Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services. It offers standard and radiation sources for medical and industrial sectors; medical imaging and spect diagnostics, industrial analytical and instrument, high activity CS-137 and CO-60, and oil well logging sources; blood irradiators and environmental disposal source services; and bulk isotopes as well as calibration related sources for radioisotopes. In addition, the company offers Tc-99m generators and supplies, trade in raw isotopes and other products, and services. It serves medical, scientific, and industrial applications. The company was formerly known as Eckert & Ziegler Strahlen- und Medizintechnik AG and changed its name to Eckert & Ziegler SE in March 2024. Eckert & Ziegler SE was founded in 1992 and is headquartered in Berlin, Germany.
Metrics to compare | EUZG | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEUZGPeersSector | |
|---|---|---|---|---|
P/E Ratio | 23.4x | 16.6x | −0.6x | |
PEG Ratio | 2.98 | 0.27 | 0.00 | |
Price/Book | 4.3x | 2.0x | 2.6x | |
Price / LTM Sales | 3.3x | 1.4x | 3.4x | |
Upside (Analyst Target) | 35.8% | 54.0% | 41.5% | |
Fair Value Upside | Unlock | 15.4% | 4.2% | Unlock |